Home  |  Contact

Cellosaurus ZR-75-1 Tam1 (CVCL_A4AL)

[Text version]

Cell line name ZR-75-1 Tam1
Accession CVCL_A4AL
Resource Identification Initiative To cite this cell line use: ZR-75-1 Tam1 (RRID:CVCL_A4AL)
Comments Population: Caucasian.
Selected for resistance to: ChEBI; CHEBI:41774; Tamoxifen.
Omics: Deep exome analysis.
Sequence variations
  • Mutation; HGNC; 5173; HRAS; Simple; p.Glu162Lys (c.484G>A); ClinVar=VCV001034833; Zygosity=Homozygous (from parent cell line).
  • Mutation; HGNC; 9588; PTEN; Simple; p.Leu108Arg (c.323T>G); Zygosity=Homozygous (from parent cell line).
Disease Invasive breast carcinoma of no special type (NCIt: C4194)
Derived from metastatic site: Ascites.
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Parent: CVCL_0588 (ZR-75-1)
Sex of cell Female
Age at sampling 63Y
Category Cancer cell line
STR profile Source(s): ATCC

Markers:
AmelogeninX
CSF1PO10,11
D5S81813
D7S82010,11
D13S3179
D16S53911
TH017,9.3
TPOX8
vWA16,18

Run an STR similarity search on this cell line
Publications

PubMed=27378269; DOI=10.1186/s12885-016-2452-5
Kangaspeska S., Hultsch S., Jaiswal A., Edgren H., Mpindi J.P., Eldfors S., Bruck O., Aittokallio T., Kallioniemi O.-P.
Systematic drug screening reveals specific vulnerabilities and co-resistance patterns in endocrine-resistant breast cancer.
BMC Cancer 16:378.1-378.17(2016)

Cross-references
Cell line collections ATCC; CRL-3438
Encyclopedic resources Wikidata; Q105511864
Entry history
Entry creation12-Jan-2021
Last entry update23-Sep-2021
Version number3